Financial PerformanceThe company produced a net loss of ~$47M, widening over 300% y/y, primarily due to a significant goodwill impairment charge.
Investor SentimentMaintaining the timeline for their core gene-edited trait and sustainable ingredient opportunities is crucial, as delays could impact investor sentiment.
Workforce ReductionCibus has continued its reduction in force, lowering headcount by 34 employees, to right-size the business.